JP2022527449A5 - - Google Patents

Info

Publication number
JP2022527449A5
JP2022527449A5 JP2021556729A JP2021556729A JP2022527449A5 JP 2022527449 A5 JP2022527449 A5 JP 2022527449A5 JP 2021556729 A JP2021556729 A JP 2021556729A JP 2021556729 A JP2021556729 A JP 2021556729A JP 2022527449 A5 JP2022527449 A5 JP 2022527449A5
Authority
JP
Japan
Prior art keywords
binding fragment
antigen
antibody
cdr
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527449A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023897 external-priority patent/WO2020191306A1/en
Publication of JP2022527449A publication Critical patent/JP2022527449A/ja
Publication of JP2022527449A5 publication Critical patent/JP2022527449A5/ja
Pending legal-status Critical Current

Links

JP2021556729A 2019-03-21 2020-03-20 細胞結合剤－薬物複合体の調製方法 Pending JP2022527449A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962821707P 2019-03-21 2019-03-21
US62/821,707 2019-03-21
US201962856942P 2019-06-04 2019-06-04
US62/856,942 2019-06-04
PCT/US2020/023897 WO2020191306A1 (en) 2019-03-21 2020-03-20 Methods of preparing cell-binding agent-drug conjugates

Publications (2)

Publication Number Publication Date
JP2022527449A JP2022527449A (ja) 2022-06-02
JP2022527449A5 true JP2022527449A5 (enExample) 2023-03-29

Family

ID=70285970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556729A Pending JP2022527449A (ja) 2019-03-21 2020-03-20 細胞結合剤－薬物複合体の調製方法

Country Status (11)

Country Link
US (2) US11833214B2 (enExample)
EP (1) EP3941527A1 (enExample)
JP (1) JP2022527449A (enExample)
KR (1) KR20220022112A (enExample)
CN (1) CN113631194A (enExample)
AU (1) AU2020240310A1 (enExample)
CA (1) CA3133802A1 (enExample)
IL (1) IL286560A (enExample)
SG (1) SG11202109569RA (enExample)
TW (1) TW202102270A (enExample)
WO (1) WO2020191306A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
US11478553B2 (en) 2019-02-15 2022-10-25 Wuxi Biologies Ireland Limited Process for preparing antibody-drug conjugates with improved homogeneity
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202302155A (zh) * 2021-03-08 2023-01-16 美商伊繆諾金公司 用於增加靶向ａｄａｍ９之免疫結合物治療癌症之功效的方法
BR112023021475A2 (pt) * 2021-04-16 2023-12-19 Novartis Ag Conjugados anticorpo-fármaco e métodos para produzir os mesmos
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2026055183A1 (en) 2024-09-03 2026-03-12 Vir Biotechnology, Inc Antiviral compositions and methods of using the same

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
US6355780B1 (en) 1995-02-22 2002-03-12 Yeda Research And Development Co. Ltd. Antibodies to the death domain motifs of regulatory proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
US7384549B2 (en) 2005-12-29 2008-06-10 Spf Innovations, Llc Method and apparatus for the filtration of biological solutions
US7897568B2 (en) 2006-03-03 2011-03-01 Vinay K. Singh Compositions for treatment of cancer
CA2655379A1 (en) 2006-06-22 2007-12-27 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
US8231787B2 (en) 2008-05-06 2012-07-31 Spf Innovations, Llc Tangential flow filtration system
KR101098335B1 (ko) 2008-07-18 2011-12-26 성균관대학교산학협력단 신코나 기재 이작용성 유기 촉매 및 이를 이용한 메소-고리산무수물의 비대칭 고리 열림 반응을 통한 키랄성헤미에스터의 제조방법
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
JP2013514788A (ja) 2009-12-23 2013-05-02 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法２
TWI622402B (zh) 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
CA2795349C (en) * 2010-04-15 2016-11-29 Seattle Genetics, Inc. Targeted pyrrolobenzodiazepine conjugates
US8569227B2 (en) 2010-04-30 2013-10-29 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
BR112013025415B1 (pt) 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
NZ718283A (en) 2013-09-25 2022-05-27 Cytomx Therapeutics Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US9562073B2 (en) 2014-01-31 2017-02-07 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
JP6685924B2 (ja) * 2014-04-11 2020-04-22 メディミューン，エルエルシー システイン操作抗体を含むコンジュゲート化合物
AU2015311987B2 (en) * 2014-09-03 2020-06-04 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
KR102508023B1 (ko) * 2014-09-03 2023-03-10 이뮤노젠 아이엔씨 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
WO2016036804A1 (en) * 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
AU2016285552B2 (en) * 2015-06-29 2022-10-13 Immunogen, Inc. Anti-CD123 antibodies and conjugates and derivatives thereof
SMT202000614T1 (it) * 2015-06-29 2021-01-05 Immunogen Inc Coniugati di anticorpi ingegnerizzati con cisteina
RU2021101009A (ru) * 2015-08-12 2021-02-20 Пфайзер Инк. Кэпированные и некэпированные цистеины антитела, и их применение в конъюгации антитело - лекарственное средство
WO2018098258A2 (en) * 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
PL3558391T3 (pl) * 2016-12-23 2022-05-16 Immunogen, Inc. Immunokoniugaty skierowane wobec białka adam9 i sposoby ich stosowania
TWI781145B (zh) * 2017-02-28 2022-10-21 美商伊繆諾金公司 具有自分解肽連接子之類美登素衍生物及其結合物
WO2018195243A1 (en) * 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
US11274121B2 (en) * 2018-01-12 2022-03-15 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
MX2020013466A (es) * 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.

Similar Documents

Publication Publication Date Title
JP2022527449A5 (enExample)
CN118829450A (zh) 一种依喜替康衍生物-抗体偶联物及其医药用途
JP2022061992A5 (enExample)
JP2025183307A5 (enExample)
JP2026026483A (ja) 標的化デンドリマー複合体
CN113816990B (zh) 修饰的氨基酸及其在adc中的应用
JP2016531914A5 (enExample)
HRP20230275T1 (hr) Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina
RU2015119557A (ru) Конъюгаты лекарственное вещество-белок
JP2025138630A5 (enExample)
RU2018102358A (ru) Нацеленные конъюгаты ksp ингибиторов
RU2009148597A (ru) Новые показания к применению при лечении антителами против il-1-бета
JP2024509169A5 (enExample)
RU2008120625A (ru) НОВОЕ ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ИЛ-1β
CN121001750A (zh) 杂环类化合物及其制备方法和用途
CN120835792A (zh) 抗体-药物偶联物靶向治疗前列腺癌和其他肿瘤
CN119343149A (zh) 用于编程化管理抗体二硫键位点特异性修饰的方法
CN120957761A (zh) 具有靶向作用的偶联物及其制备方法和用途
CN114106088A (zh) 基于溴甲基吡嗪的药物偶联物及adc
CA2901312C (en) Activated carbon filtration for purification of benzodiazepine adcs
JP2025508779A5 (enExample)
CN120225226A (zh) B7-h3抗体药物偶联物及其应用
JP2023542910A5 (enExample)
JP2026508115A (ja) リンカー薬物、その抗体－薬物コンジュゲート、並びにそれらの調製方法及び使用
RU2021130006A (ru) Способы получения конъюгатов клеточно-связывающий агент-лекарственное средство